Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

Leukemia. 2018 Feb;32(2):562-565. doi: 10.1038/leu.2017.306. Epub 2017 Oct 9.

¹ Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
² Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
³ Research and Development, Amgen Research (Munich) GmbH, Munich, Germany.
⁴ Pediatric Hematology/Oncology, Primary Children's Hospital, Salt Lake City, UT, USA.
⁵ Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
⁶ Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
⁷ Comprehensive Cancer Center Mainfranken, University Hospital, Würzburg, Germany.
⁸ Research and Development, Amgen Inc., Washington, DC, USA.
⁹ Research and Development, Amgen Inc., Thousand Oaks, CA, USA.
¹⁰ Division of Hematology, Mayo Clinic, Rochester, MN, USA.

No abstract available

Publication types